Cholesterol and Metabolic Health

This is the part of amla's story with actual randomised trials behind it, which puts it ahead of most herbal supplements. It is also the part where the gap between “statistically significant” and “clinically established” is widest, and where the honest reading requires paying attention to trial design rather than headline p-values.

Here is the summary you can hold in your head. Across five small randomised trials, amla extract consistently lowers total cholesterol, LDL cholesterol, triglycerides and fasting glucose, and raises HDL cholesterol. The effects are real in the sense that they show up repeatedly. They are also measured over three to twelve weeks, in samples of 10 to 98 people, almost entirely at a small number of centres in one country, and on blood markers rather than heart attacks. And the one independent European trial of a Triphala-containing product found nothing.

All of which is worth knowing before you decide whether to take it — and none of which is a reason to stop a statin.

Table of Contents

1. What the Evidence Base Consists Of
2. The Meta-Analysis, and Why Five Trials Is Not Many
3. The Dyslipidaemia Trial in Detail
4. Amla Versus Simvastatin — Read the Design First
5. Blood Sugar
6. Endothelial Function and Inflammation
7. Blood Pressure
8. The Negative Trial, and Why It Matters Most
9. The Geography Problem
10. Plausible Mechanisms
11. Dosing, Forms and What to Buy
12. Cautions and Drug Interactions
13. Key Research Papers
14. Connections

What the Evidence Base Consists Of

Before any individual result, the shape of the whole literature:

Two features jump out. The first is that the largest amla lipid trial had 98 participants — a statin trial would have thousands. The second is the single-country concentration, which the geography section deals with directly.

The Meta-Analysis, and Why Five Trials Is Not Many

Setayesh and colleagues searched Web of Science, PubMed, Scopus and Embase up to December 2022 for randomised controlled trials of amla supplementation, and pooled what they found using a random-effects model. Their results:

• Significant reduction in C-reactive protein (p = 0.002)
• Significant reduction in fasting blood glucose (p < 0.001)
• Significant reduction in LDL cholesterol (p < 0.001)
• Significant reduction in total cholesterol (p < 0.001)
• Significant reduction in triglycerides (p < 0.001)
• Significant increase in HDL cholesterol (p < 0.001)

That looks like a clean sweep, and there is something genuinely encouraging about a herb moving every metabolic marker in the same direction. But the details the authors themselves state are what turn it from a conclusion into a starting point:

1. Five trials. Not five hundred. A meta-analysis is only as good as what goes into it, and pooling five small studies gives you a more precise estimate of a possibly biased number, not a more reliable one. Publication bias — the tendency for positive results to get published and null ones to sit in a drawer — cannot be meaningfully assessed with five studies.
2. Three to twelve weeks. Cardiovascular risk plays out over decades. Twelve weeks tells you a marker moved; it cannot tell you whether the movement persists, whether tolerance develops, or whether anything downstream changes.
3. Participants averaged 40–58 years with a mean BMI of about 25.5. That is a relatively healthy, mildly overweight, middle-aged population. Results in that group do not automatically apply to someone with established coronary disease, familial hypercholesterolaemia, or diabetes on multiple drugs.
4. No hard outcomes. Nothing in this literature measures heart attacks, strokes or deaths. Every result is a blood test.

The last point deserves emphasis, because it is where herbal-supplement claims most often overreach. LDL cholesterol is a surrogate marker — useful because lowering it with certain drug classes reliably lowers cardiovascular events. That relationship is established for statins, ezetimibe and PCSK9 inhibitors through enormous outcome trials. It has never been demonstrated for amla, and cannot be assumed. Plenty of interventions have lowered a lipid number without helping anyone; that is precisely why outcome trials exist.

The Dyslipidaemia Trial in Detail

The single most useful study on this page is Upadya and colleagues, published in 2019 — a randomised, double-blind, placebo-controlled, multicentre trial in India.

What they did

• 98 patients with dyslipidaemia, randomised to amla extract or matching placebo.
• 500 mg twice daily for 12 weeks. The extract was described as composed of polyphenols, triterpenoids and oils, as found in the fresh wild fruit.
• Endpoints: full lipid profile, plus apolipoprotein B, apolipoprotein A1, coenzyme Q10, high-sensitivity CRP, fasting blood sugar, homocysteine and TSH.

What they found

• Total cholesterol significantly lower than placebo (p = 0.0003)
• Triglycerides significantly lower (p = 0.0003)
• LDL cholesterol significantly lower (p = 0.0064)
• VLDL cholesterol significantly lower (p = 0.0001)
• Atherogenic index of plasma down 39% (p = 0.0177)
• Coenzyme Q10 unchanged (p = 0.29) — the authors' point being that statins reduce CoQ10 and amla did not
• A general downward trend in fasting blood sugar, though only 8 participants were in the pre-diabetic or diabetic range, which the authors explicitly said needed confirming in a larger study

What to hold against it

• 98 people for 12 weeks measures blood chemistry, not cardiovascular events.
• The trial was registered retrospectively — with the Clinical Trials Registry of India in April 2015, after enrolment had begun. Prospective registration exists to stop outcomes being chosen after the data are seen. Retrospective registration is common and not damning, but it removes a safeguard.
• The intervention was one specific commercial extract. Nothing in the result transfers to amla powder, juice or fresh fruit.
• The coenzyme Q10 finding is real but is being used rhetorically. “It did not lower CoQ10” is not evidence it works as well as a statin; it is evidence it does not share one specific statin side effect.

Fair verdict: a well-conducted small trial with a consistent result, worth taking seriously as a reason for further study, and not sufficient on its own to change anyone's treatment.

Amla Versus Simvastatin — Read the Design First

The study most often quoted to suggest amla rivals a statin is Gopa, Bhatt and Hemavathi, 2012, in the Indian Journal of Pharmacology. The headline — that amla lowered lipids comparably to simvastatin and lowered blood pressure more — is exactly what a supplement marketer wants. The design is what you need.

What was done: 60 patients with type II hyperlipidaemia (total cholesterol above 240 mg/dL and LDL above 130 mg/dL). Forty received a 500 mg amla capsule daily for 42 days; twenty received simvastatin 20 mg daily for 42 days. Lipids and cardiovascular parameters were measured before and after.

What was found: both treatments significantly reduced total cholesterol, LDL, triglycerides and VLDL and raised HDL, all against their own baselines. Both reduced blood pressure, with a more marked effect reported in the amla group.

Now the design problems, which are substantial:

1. There is no placebo group. Every comparison that matters is against each group's own starting values. People enrolled in a lipid trial change their diet, take their pills, and get measured on a machine that has its own variability. Some of the improvement in both arms is that, not the drug.
2. Unequal allocation, 40 versus 20. Twenty people is a very small comparison arm, which widens the uncertainty on the simvastatin side and makes “comparable to simvastatin” a weak claim statistically.
3. Forty-two days. Six weeks.
4. Comparable within-group significance is not equivalence. Two treatments can both be “significantly different from baseline” while differing greatly from each other. Demonstrating non-inferiority to a statin requires a specifically designed non-inferiority trial with a pre-stated margin and hundreds of participants. This is not that.

How to read it: as a small, early, hypothesis-generating study from a pharmacology department — useful, published in good faith, and radically over-quoted. If someone tells you a study showed amla works as well as a statin, this is almost certainly the study, and now you know what it actually was.

Blood Sugar

The pooled meta-analysis found a significant reduction in fasting blood glucose, and the Upadya trial saw a downward trend. The most-cited standalone glucose study is Akhtar and colleagues, 2011, from the University of Sargodha in Pakistan — and it is worth reading carefully, partly because it is one of the few non-Indian entries in this literature.

What was done: normal volunteers and people with type 2 diabetes were given 1, 2 or 3 g of amla powder per day for 21 days.

What was found: significant falls in fasting and 2-hour post-meal glucose in both groups at day 21 versus their own baselines. Total cholesterol and triglycerides fell in those on 2 or 3 g. HDL rose and LDL fell at those doses. A dose-response pattern was visible.

The limitation, stated plainly: there was no placebo or control group. All comparisons are before-and-after. In a 21-day study where participants know they are being monitored, before-and-after glucose improvements are exactly what you would expect even from an inert capsule. The dose-response pattern is the most interesting feature, because a dose-response is harder to explain by attention alone — but it is not a substitute for a control arm.

What this means practically. Do not take amla as a treatment for diabetes. Do take the glucose signal seriously as an interaction issue: if you are on metformin, a sulfonylurea, a gliptin or insulin and you start amla, check your glucose more often for the first two to three weeks. An additive effect that would be harmless in a healthy person can produce a hypo in someone on a sulfonylurea or insulin.

Endothelial Function and Inflammation

Usharani and colleagues in Hyderabad have produced the most mechanistically detailed human work on amla. Their 2019 trial randomised 59 people with metabolic syndrome to a standardised aqueous Phyllanthus emblica fruit extract at 250 mg or 500 mg twice daily, or placebo, for 12 weeks. Endothelial function was measured as reflection index by digital plethysmography; oxidative stress by nitric oxide, glutathione and malondialdehyde; inflammation by high-sensitivity CRP.

At 12 weeks on the 500 mg twice-daily dose they reported: nitric oxide up 50.7%, glutathione up 53.2%, malondialdehyde down 31.4%, hsCRP down 53.8%, total cholesterol down 11.1%, LDL down 21.8%, triglycerides down 19.2%, HDL up 22.2%. The 500 mg dose beat the 250 mg dose, which beat placebo. Nobody withdrew for adverse events.

An earlier trial from the same group, published in 2013, tested the extract on endothelial dysfunction and oxidative stress biomarkers in type 2 diabetes.

What to make of it. A clean dose-response across multiple independent biomarkers is a genuinely encouraging pattern — it is much harder to produce by chance than a single significant p-value. But:

• Every endpoint is a surrogate. Reflection index is a proxy for arterial stiffness; malondialdehyde is a proxy for lipid oxidation. None is an outcome anyone experiences.
• Fifty-nine people, one centre.
• The 2019 study was registered retrospectively, and the study medication and biomarker kits were supplied by the extract's manufacturer — disclosed by the authors, which is the right thing to do, and still a fact to weigh.
• The effect sizes are large for a botanical. Large effects in small single-centre trials are the ones that most often shrink on replication.

Blood Pressure

Shanmugarajan and colleagues ran a randomised, double-blind, placebo-controlled trial of Phyllanthus emblica extract as an add-on therapy in people already being treated for essential hypertension, reporting antihypertensive and other “pleiotropic” effects.

The design word that matters is add-on. Everyone in the trial was on antihypertensive medication; amla was layered on top. That is the honest way to test a supplement in a condition where withholding treatment would be unethical, and it means the result can only ever support amla as an addition, never a replacement.

The practical consequence is a real one and cuts both ways. An additive blood-pressure effect is what the trial was designed to find, so if you add amla to existing antihypertensives, watch for lightheadedness on standing, especially in the first fortnight and especially if you are older or on a diuretic. Check your blood pressure at home rather than assuming.

The Negative Trial, and Why It Matters Most

Everything above is positive. Here is the study that stops it becoming a sales page — and it is arguably the most informative trial in this whole literature.

In 2021, Donato and colleagues at the University of Brescia published a placebo-controlled, double-blind, randomised trial of a preparation combining guggul (Commiphora mukul) and Triphala — that is, Terminalia chebula, Terminalia bellirica and Phyllanthus emblica — in people with high cholesterol.

The design

• 90 participants at low-to-moderate cardiovascular risk, randomised to the herbal preparation or placebo three times daily for 3 months, with 3 further months of follow-up.
• Primary outcomes: total, LDL and HDL cholesterol. Secondary: BMI, waist circumference, adverse events.
• Conducted in Italy, by a public-health and epidemiology department with no stake in the product.

The result

• Total cholesterol fell 1.9% on placebo and 3.3% on the herbal preparation.
• LDL cholesterol fell 4.9% on placebo and 4.8% on the herbal preparation — a difference of essentially zero, in the wrong direction.
• No difference in BMI or waist circumference.
• Two participants (4.3%) in the treatment group developed a hypersensitivity rash. None did on placebo.
• The authors' conclusion, verbatim in substance: three months of guggul and Triphala did not show better effects than placebo.

Reading it honestly, in both directions

This is not a refutation of the amla extract trials, and it would be dishonest to present it as one. It tested a different product (guggul plus Triphala, not amla extract), a different dose form, and a population that was healthier than the dyslipidaemic patients in the Upadya trial. Triphala is one-third amla by weight; the amount of amla-derived polyphenol delivered may have been far below what the extract trials used.

What it is, and this is why it belongs here, is a demonstration of three things at once:

1. Look at the placebo arm. Cholesterol fell by 1.9% and LDL by 4.9% on placebo. That is the size of drift you get from enrolment, monitoring and regression to the mean alone. Any uncontrolled before-and-after study — like the Pakistani glucose study, or the amla-versus-simvastatin comparison — would have called that a result.
2. Independent replication changes answers. An epidemiology department in Brescia with nothing to gain measured the same class of intervention and found nothing.
3. These preparations are not side-effect free. A 4.3% rate of hypersensitivity rash, against zero on placebo, is a real adverse-event signal in a product widely described as gentle and food-like.

The Geography Problem

Look again at the table at the top of this article. Of the studies supporting amla's metabolic benefits, essentially all were conducted in India, with several from the same city and one research group appearing repeatedly across amla and baheda trials. The single non-Indian positive study is the uncontrolled Pakistani one. The single independent Western trial is negative.

This is a pattern worth naming, not an accusation. Indian pharmacology departments study Indian medicinal plants because that is what is in front of them, funded and culturally important, and expecting otherwise would be unreasonable. Much of that work is competently done and honestly reported.

But the pattern has a documented consequence. Across complementary medicine broadly, trials conducted in the country where a therapy originates report positive results at strikingly higher rates than trials conducted elsewhere, and effect sizes shrink when the same intervention is tested by independent teams in different settings. The reasons are mundane and mostly innocent — enthusiasm, small samples, unblinded assessments, publication preferences, product quality varying between suppliers — and the effect is real regardless of cause.

What to do with that. Not dismiss the findings. Discount them appropriately, and ask the question that would settle it: has anyone outside India run an adequately powered, prospectively registered, placebo-controlled trial of a standardised amla extract on lipids? At the time of writing, no. Until someone does, amla's metabolic benefits should be filed as promising and unconfirmed.

Plausible Mechanisms

Mechanism does not prove benefit, but a plausible mechanism makes a clinical signal easier to believe. Several have been proposed for amla, at varying evidence levels — all laboratory or animal work unless stated:

• Digestive enzyme inhibition. Triphala constituents inhibit α-amylase and α-glucosidase in laboratory assays. Those enzymes break starch into absorbable sugar; slowing them blunts the post-meal glucose spike. This is the mechanism of the drug acarbose, so the pharmacology is well precedented. In vitro and animal.
• Aldose reductase inhibition. Suryanarayana and colleagues reported in 2004 that amla tannoid principles inhibit aldose reductase, the enzyme that converts glucose to sorbitol in the polyol pathway — implicated in diabetic cataract and neuropathy. Enzyme and animal work.
• Reduced oxidative modification of LDL. Oxidised LDL is more atherogenic than native LDL. Polyphenols could plausibly slow that oxidation, and the Usharani trials' malondialdehyde reductions are consistent with it. Surrogate markers in humans.
• Nitric oxide and endothelial signalling. The 41–51% increases in nitric oxide reported in the metabolic syndrome trial would, if real and sustained, improve vessel relaxation. Surrogate marker.
• Bile acid binding by tannins. Tannins can bind bile acids in the gut, forcing the liver to make more from cholesterol — the mechanism of bile acid sequestrant drugs. Chemically plausible for a fruit this tannin-rich; not specifically demonstrated for amla in humans.
• Anti-inflammatory effects, reflected in the CRP reductions in both the meta-analysis and the Usharani trials.

Notice that none of these mechanisms is amla-specific. Most would apply to any tannin-rich plant food — which is one reason a diet with more whole plant food in it is better-evidenced than any single supplement in it.

Dosing, Forms and What to Buy

Amla is unusual among herbs on this site in that the dose comes from trials rather than tradition.

Label checklist

• Binomial: Phyllanthus emblica or Emblica officinalis — the same plant.
• Part: fruit. Not leaf, not branch, not “whole plant”.
• A standardisation marker with a number. “Standardised extract” with nothing standardised to is not a specification.
• Milligrams per capsule, so you can actually reach 500 mg twice daily without arithmetic gymnastics.
• Third-party heavy-metal testing, with a certificate of analysis available.
• No hidden blend. If amla is one of eight herbs at an undisclosed per-herb dose, no trial on this page applies to it.

How to try it sensibly

1. Get a baseline lipid panel first. Without one you cannot know whether anything changed, and you will be left guessing.
2. Start the extract at 500 mg twice daily and keep everything else — diet, exercise, medication — constant, so any change is interpretable.
3. Recheck at 12 weeks, matching the trial duration.
4. If nothing has moved, stop. A supplement that does not do the thing you bought it for is just an expense and an interaction risk.
5. Tell your doctor you are taking it, particularly if you are on a statin, a blood thinner, or diabetes or blood-pressure medication.

Cautions and Drug Interactions

1. Do not stop or reduce a statin, or any other prescribed medication, to take amla. Statins have outcome evidence measured in cardiovascular events across tens of thousands of people. Amla has 98 people for 12 weeks and a blood test. These are not comparable claims, and swapping one for the other trades a proven benefit for an unproven one.
2. Bleeding risk — the best-documented interaction. Fatima and colleagues ran a randomised open-label crossover study in 10 people with type 2 diabetes, testing 500 mg P. emblica extract alone and combined with clopidogrel or aspirin. Platelet aggregation fell significantly with single and repeated doses, and bleeding and clotting times were prolonged with all treatments. The study is small and was open-label, but the direction is consistent and mechanistically expected. If you take warfarin, a DOAC, clopidogrel, aspirin or any antiplatelet, tell your doctor before starting amla, and stop it about two weeks before planned surgery or dental extraction.
3. Glucose-lowering medication. Plausible additive effect. Monitor glucose more frequently for the first two to three weeks on metformin, sulfonylureas, gliptins or insulin, and know your hypo symptoms.
4. Blood-pressure medication. Amla was tested precisely as an add-on to antihypertensives, so additive lowering is expected. Watch for dizziness on standing.
5. Iron absorption. Amla's galloyl tannins inhibit non-haem iron absorption in a strongly dose-dependent way. Separate extracts and Triphala from iron supplements and iron-rich meals by about two hours. Details in the Triphala article.
6. Hypersensitivity. The Italian trial recorded rash in 4.3% of the treated group and none on placebo. Stop for any new rash, itching or swelling.
7. Kidney stones. Vitamin C raises urinary oxalate and amla contains oxalate. If you form calcium-oxalate stones, discuss before taking concentrated products.
8. Reflux. Amla is very sour. Some people find it aggravating even though it has been studied as a reflux treatment.
9. Pregnancy and breastfeeding. Food amounts are eaten routinely across South Asia. No safety data exist for concentrated extracts in pregnancy — so food yes, supplements no.
10. Separate from other medication by about two hours as a general tannin-binding precaution, since tannins can reduce absorption of a range of drugs.
11. Product quality. Heavy-metal contamination of imported Ayurvedic products is documented in the peer-reviewed literature. Buy tested product.

Key Research Papers

Every identifier below was verified live against NCBI E-utilities before publication — first author, title, journal and year all had to match.

The pooled evidence

1. Setayesh L, Haghighat N, Rasaei N, et al. The impact of Emblica officinalis (Amla) on lipid profile, glucose, and C-reactive protein: a systematic review and meta-analysis of randomized controlled trials. Diabetes & Metabolic Syndrome. 2023;17(3):102729. Five RCTs; significant reductions in CRP, fasting glucose, LDL, total cholesterol and triglycerides; HDL increased. Participants 40–58 years, mean BMI 25.5, interventions 3–12 weeks.

Lipid trials

1. Upadya H, Prabhu S, Prasad A, Subramanian D, Gupta S, Goel A. A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia. BMC Complementary and Alternative Medicine. 2019;19(1):27. n = 98, 500 mg twice daily, 12 weeks; TC, TG, LDL and VLDL all significantly below placebo; 39% fall in atherogenic index; CoQ10 unchanged. Retrospectively registered.
2. Gopa B, Bhatt J, Hemavathi KG. A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. Indian Journal of Pharmacology. 2012;44(2):238–242. 60 patients, 40 on amla vs 20 on simvastatin, 42 days, no placebo arm; both improved against baseline.
3. Donato F, Raffetti E, Toninelli G, Festa A, Scarcella C, Castellano M. Guggulu and Triphala for the treatment of hypercholesterolaemia: a placebo-controlled, double-blind, randomised trial. Complementary Medicine Research. 2021;28(3):216–225. n = 90, 3 months, Italy. Negative — TC fell 1.9% placebo vs 3.3% treatment; LDL fell 4.9% vs 4.8%, no between-group difference. Hypersensitivity rash in 4.3% vs 0%.

Glucose, endothelium and blood pressure

1. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. International Journal of Food Sciences and Nutrition. 2011;62(6):609–616. 1, 2 or 3 g/day of powder for 21 days, Pakistan; uncontrolled, comparisons against baseline only.
2. Usharani P, Merugu PL, Nutalapati C. Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome. BMC Complementary and Alternative Medicine. 2019;19(1):97. n = 59, 250 vs 500 mg twice daily, 12 weeks; dose-dependent improvements in reflection index, NO, GSH, MDA, hsCRP and lipids. Retrospectively registered; study medication supplied by the manufacturer.
3. Usharani P, Fatima N, Muralidhar N. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes, Metabolic Syndrome and Obesity. 2013;6:275–284.
4. Shanmugarajan D, Girish C, Harivenkatesh N, Chanaveerappa B, Prasanna Lakshmi NC. Antihypertensive and pleiotropic effects of Phyllanthus emblica extract as an add-on therapy in patients with essential hypertension. Phytotherapy Research. 2021;35(6):3275–3285. Add-on design — supports addition, never replacement.
5. Manjunatha S, Jaryal AK, Bijlani RL, Sachdeva U, Gupta SK. Effect of Chyawanprash and vitamin C on glucose tolerance and lipoprotein profile. Indian Journal of Physiology and Pharmacology. 2001;45(1):71–79.

Safety and mechanism

1. Fatima N, Pingali U, Muralidhar N. Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. Phytomedicine. 2014;21(5):579–585. Randomised open-label crossover, n = 10; significant antiplatelet effect alone and with clopidogrel or aspirin; bleeding and clotting times prolonged.
2. Suryanarayana P, Kumar PA, Saraswat M, Petrash JM, Reddy GB. Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract. Molecular Vision. 2004;10:148–154. Enzyme and animal work.
3. Brune M, Rossander L, Hallberg L. Iron absorption and phenolic compounds: importance of different phenolic structures. European Journal of Clinical Nutrition. 1989;43(8):547–557. Human iron absorption; galloyl-group dose-response.
4. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA. 2008;300(8):915–923.
5. Hegde SN, K LD, Choudhary M, Menon N, Singh G. A comprehensive metabolome profiling of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica to explore the medicinal potential of Triphala. Scientific Reports. 2024;14(1):31635.

Live PubMed Searches

1. Amla and lipid profile
2. Amla and diabetes trials
3. Amla and endothelial function
4. Amla and blood pressure
5. Triphala and cholesterol
6. Herbal supplements and bleeding risk
7. α-glucosidase inhibition and post-meal glucose
8. Country-of-origin effects in complementary medicine trials
9. Surrogate endpoints versus cardiovascular outcomes
10. Amla safety and toxicity

Connections

• All Herbs
• Amla Benefits — the hub, with the evidence map.
• Amla / Indian Gooseberry (Phyllanthus emblica) — the main article.
• Vitamin C and Antioxidant Chemistry — why the antioxidant numbers behind these mechanisms are contested.
• Triphala and Digestive Use — including the negative cholesterol trial in its Triphala context.
• Hair, Skin and Traditional Cosmetic Use — the other modern trial.
• Haritaki (Terminalia chebula) — the first Triphala fruit.
• Baheda (Terminalia bellirica) — the second, and the least researched.
• Chanca Piedra (Phyllanthus niruri) — same genus, different plant, different use.
• Vitamin C — the nutrient amla is famous for.

Back to Table of Contents